Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $11.0052W HIGH $16.75
Volume
1.95 M
Value Traded
7.63 M
Short % Float
13.43%
-10.51%Week
-22.67%1 Month
-8.35%3 Month
-0.71%6 Month
+20.98%5 Year
+20.98%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.61 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
1.15 B
Total Shares
128.35 M
Float Shares
55.21 M
Insiders
56.98%
Institutions
25.08%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
GENB Catalyst Timeline
Dated clinical, regulatory and corporate events for Generate Biomedicines, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Generate Biomedicines, Inc.
20Total events
3Upcoming
2Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 2
Event history 13
▲Partnership / LicenseCorporate
Zealand Pharma and Generate Biomedicines enter collaboration and license agreement for AI-engineered protein therapeutics in metabolic diseases
obesity and other metabolic diseasessource ↗
▲First Patient DosedGB-5267Trial
First patient dosed in Phase 1 trial of GB-5267 in ovarian cancer
platinum-resistant ovarian cancersource ↗
▲Trial InitiationGB-5267Trial
Phase 1 trial of GB-5267 initiated at Roswell Park
platinum-resistant ovarian cancersource ↗
●Enrollment UpdateGB-0895Trial
Recruitment underway across all six global regions for SOLAIRIA-1 and SOLAIRIA-2
severe asthmasource ↗
▲Enrollment CompleteGB-4362Trial
All patients enrolled in first cohort of Phase 1 study for GB-4362
locally advanced or metastatic urothelial cancersource ↗
▲First Patient DosedGB-4362Trial
Initial patients dosed in first cohort of Phase 1 study for GB-4362
locally advanced or metastatic urothelial cancersource ↗
●Trial InitiationGB-5267Trial
Phase 1 study of GB-5267 is now recruiting
advanced, platinum-resistant ovarian cancersource ↗
▲Fast Track DesignationGB-4362Designation
GB-4362 received FDA Fast Track designation
prevention and/or reduction of enfortumab vedotin-induced toxicity in urothelial cancersource ↗
▲Partnership / LicenseCorporate
Novartis advanced a biologic designed with Generate Platform into preclinical pipeline
▲Preclinical PoCPreclinical
Novartis advances biologic designed with Generate Platform into preclinical pipeline
Past FDA Catalysts and PDUFA Decisions
How GENB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-08 | GB-0895 (anti-TSLP, golukibart) | Phase 1b data readout | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
4
Drugs Scored
rNPV / MCap
Top Drug
Top 11%
Micro Cap(rank 73 of 656)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GB-0895 Small moleculeNCT07276724 | Severe Asthma | Phase 3 | RECRUITING | 1,572 | Dec 1, 2028 | ||||||
| GB-0895 Monoclonal antibodyNCT07116889 | Asthma | Phase 1 | ACTIVE NOT_RECRUITING | 156 | May 1, 2027 | ||||||
| GB-7624 Small moleculeNCT06920693 | Atopic Dermatitis (AD) | Phase 1 | ACTIVE NOT_RECRUITING | 40 | Dec 30, 2026 | ||||||
| GB-4362 Small moleculeNCT07484022 | Advanced Urothelial Cancer | Phase 1 | RECRUITING | 37 | Dec 1, 2027 | ||||||
| GB-0669 Small moleculeCompletedNCT07050511 | SARS CoV-2 | Phase 1 | COMPLETED | 51 | Nov 22, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every GENB program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ARNOLD FRANCESDirector | Sell | -1,000 231,472 held | $16.00 | 09/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GENB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0.1 % | 24.02 M | 1.42 M |
GENB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GENB ranks across every disease it competes in
Competitive Position is a premium feature
See how GENB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGENB News
GENB▲ +2.2%today
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Zealand Pharma and Generate Biomedicines have entered a collaboration to develop protein therapeutics for metabolic diseases using AI. The agreement includes an upfront payment of $30 million and potential milestones totaling nearly $1.2 billion. This partnership aims to leverage Zealand's metabolic health expertise and Generate's AI capabilities to create innovative drug candidates.
Read more →GENB▲ +2.2%today
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Generate Biomedicines has entered a collaboration with Zealand Pharma to develop multispecific protein therapeutics for obesity and metabolic diseases. The partnership will leverage Generate's AI platform alongside Zealand's expertise in metabolic health. Generate will receive an upfront payment of $30 million and potential milestone payments totaling up to $1.2 billion. This agreement broadens Zealand's capabilities beyond peptides.
Read more →GENB▼ -8.1%on this news
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
Roswell Park and Generate Biomedicines have initiated a clinical trial for GB-5267, an IL-18 armored CAR T-cell therapy targeting ovarian cancer. The first patient has been dosed, marking a significant step in addressing treatment challenges in solid tumors. This therapy aims to avoid the side effects of traditional chemotherapy while effectively targeting MUC16, a key biomarker in ovarian cancer.
Read more →GENBGenerate Biomedicines Inc. to Participate in September Investor Conferences
Generate Biomedicines Inc. announced its participation in several upcoming investor conferences in September 2026. Key events include the Cantor Global Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference, among others. The company aims to highlight its advancements in generative biology and provide updates on its product pipeline. Live webcasts of the presentations will be accessible on their investor website.
Read more →GENBGenerate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
Generate Biomedicines Inc. reported its Q2 2026 financial results, highlighting advancements in its clinical programs, particularly the Phase 3 studies for GB-0895 in severe asthma. The company has a strong cash position of $457.4 million and is actively recruiting for multiple trials. However, it also reported a net loss of $67.3 million and a decline in revenue compared to the previous year.
Read more →GENBGenerate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
Generate Biomedicines, Inc. announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference scheduled for June 8, 2026. The event will feature a live webcast available on the company's investor website, with an archived replay to follow. Generate Biomedicines focuses on advancing programmable biology to create optimized therapeutics.
Read more →GENB▼ -11.2%on this news
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
Generate Biomedicines, Inc. reported its Q1 2026 financial results, highlighting advancements in its clinical pipeline. The company is progressing with Phase 3 trials for GB-0895 and expects to initiate patient dosing for GB-4362 in mid-2026. Despite a net loss of $61.7 million, the company has a strong cash position of $516.6 million.
Read more →GENBGenerate Biomedicines, Inc. Announces Pricing of Initial Public Offering
Generate Biomedicines, Inc. has announced the pricing of its initial public offering, offering 25 million shares at $16.00 each, aiming to raise $400 million. The IPO is set to close on March 2, 2026, with shares expected to begin trading on Nasdaq on February 27, 2026. Goldman Sachs and Morgan Stanley are leading the offering.
Read more →GENBGenerate:Biomedicines Welcomes Aarif Khakoo, MD, MBA, as Chief Scientific Officer
Generate:Biomedicines has appointed Aarif Khakoo, MD, MBA, as its new Chief Scientific Officer. Dr. Khakoo has a strong background in biotechnology, having previously led research and development at Scribe Therapeutics and held significant roles at Calico Life Sciences and Amgen. His leadership is expected to advance the company's therapeutic pipeline and enhance the Generate Platform's capabilities.
Read more →GENBGenerate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
Generate:Biomedicines announced the initiation of two global Phase 3 trials for GB-0895, a long-acting anti-TSLP antibody aimed at treating severe asthma. These studies will involve approximately 1,600 patients and focus on reducing asthma exacerbations over a 52-week period. The trials represent a significant advancement in programmable biology and the potential for improved asthma management.
Read more →GENBGenerate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma at the European Respiratory Society International Congress
Generate:Biomedicines announced the presentation of Phase 1 results for GB-0895, an AI-engineered monoclonal antibody for asthma, at the European Respiratory Society International Congress. The study showed that GB-0895 was well tolerated and demonstrated a prolonged half-life, supporting its potential for biannual dosing. Experts highlighted its promise as a treatment alternative for respiratory diseases.
Read more →GENBGenerate:Biomedicines Welcomes Laurie Lee, MD, as Chief Medical Officer for the Immunology & Inflammation Portfolio
Generate:Biomedicines has appointed Dr. Laurie Lee as the Chief Medical Officer for its immunology and inflammation portfolio. With over 17 years of experience in clinical development, Dr. Lee's expertise is expected to enhance the company's clinical strategy. Her previous roles include significant positions at CSL Behring and GlaxoSmithKline, where she led various successful clinical programs.
Read more →GENBGenerate:Biomedicines Expands Board of Directors with Appointment of Marsha Fanucci
Generate:Biomedicines has appointed Marsha Fanucci to its board of directors. Fanucci brings extensive experience in biotechnology and financial strategy, having previously held leadership roles at Millennium Pharmaceuticals and Genzyme Corp. Her expertise is expected to enhance the company's strategic growth and support the development of innovative protein therapeutics.
Read more →About Generate Biomedicines, Inc.
Headquarters101 SOUTH STREET, SUITE 900, SOMERVILLE, MA, 02143
BIOPHARMAWATCH ELITE PLUS
Trade the next GENB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime